Viking Therapeutics Inc (VKTX)

[Whalatane]

Jan 2 opinion from Larry Ramer

Viking Therapeutics (NASDAQ:VKTX) owns a potential weight-loss, cholesterol, and liver-disease treatment called VK2735. In a Phase 1 trial of the drug, the liver fat of patients taking VK2735 fell “up to 47.2%.” Moreover, the cholesterol levels of the four patients taking the highest dose of the drug dropped by an average of 21%.

Also noteworthy is that the drug was found to be “well-tolerated.”

Last month, Barron’s stated that ” Pfizer could look to make a deal with a biotech developing an anti-obesity pill, given the roadblocks its own internally-developed anti-obesity pill has hit. ”

Given the fact that weight-loss drugs are expected to be very lucrative, while Viking’s VK2735 performed quite well in its Phase I trial, I believe that Viking could easily be acquired by Pfizer (NYSE:PFE) or another large company that does not have its own highly effective obesity treatment.

--------------
Kiwi